drugset / Trial / NCT05703841

A Study of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult Participants

NCT05703841

Phase 1 Completed 30 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to assess what drug does to body when healthy Chinese participants receive single oral dose of JNJ-77242113.

Timeline

Start
2023-02-14
Primary completion
2023-04-07
Completion
2023-04-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Icotrokinra Peptide Oral

Indications

No indication recorded.